Profile data is unavailable for this security.
About the company
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
- Revenue in USD (TTM)2.07bn
- Net income in USD365.57m
- Incorporated2014
- Employees5.90k
- LocationMedpace Holdings Inc5375 Medpace WayCINCINNATI 45227-1543United StatesUSA
- Phone+1 (513) 579-9911
- Fax+1 (302) 655-5049
- Websitehttps://investor.medpace.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | 76.81m | -518.67m | 6.92bn | 376.00 | -- | 8.90 | -- | 90.04 | -25.07 | -25.07 | 3.71 | 35.64 | 0.1172 | -- | -- | 204,289.90 | -79.11 | -62.09 | -100.35 | -74.81 | 96.37 | -- | -675.24 | -- | 5.93 | -- | 0.1309 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Legend Biotech Corp (ADR) | 520.18m | -348.13m | 7.40bn | 2.40k | -- | 6.60 | -- | 14.22 | -1.91 | -1.91 | 2.85 | 6.08 | 0.291 | 9.29 | 1,434.99 | 288,990.60 | -19.47 | -37.71 | -22.25 | -47.19 | 62.88 | -- | -66.92 | -286.51 | 4.90 | -- | 0.237 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Tempus AI Inc | 640.44m | -800.71m | 9.16bn | 2.30k | -- | 168.11 | -- | 14.30 | -8.29 | -8.29 | 4.44 | 0.3459 | -- | -- | -- | -- | -- | -- | -- | -- | 53.18 | -- | -116.06 | -- | 2.55 | -14.95 | 0.891 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Revolution Medicines Inc | 742.00k | -567.06m | 9.60bn | 490.00 | -- | 6.11 | -- | 12,938.38 | -3.59 | -3.59 | 0.0047 | 9.34 | 0.0005 | -- | 4.80 | 1,962.96 | -41.28 | -29.76 | -44.46 | -32.59 | -- | -- | -76,423.31 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.06bn | 413.08m | 9.61bn | 20.00k | 23.46 | 2.54 | 12.51 | 2.37 | 8.01 | 8.01 | 78.63 | 73.97 | 0.5203 | 8.27 | 5.23 | 203,045.80 | 5.48 | 6.46 | 6.33 | 7.62 | 35.93 | 36.99 | 10.54 | 11.58 | 1.14 | 4.96 | 0.3784 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Exact Sciences Corp | 2.69bn | -214.04m | 9.75bn | 6.50k | -- | 3.04 | 5,350.26 | 3.62 | -1.17 | -1.17 | 14.70 | 17.35 | 0.4089 | 5.40 | 11.60 | 414,204.30 | -3.25 | -9.71 | -3.58 | -10.60 | 72.96 | 74.10 | -7.95 | -28.21 | 1.93 | -- | 0.4459 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Exelixis Inc | 2.08bn | 466.92m | 9.90bn | 1.31k | 22.08 | 4.35 | 20.01 | 4.75 | 1.57 | 1.57 | 6.92 | 7.96 | 0.7012 | 3.39 | 8.04 | 1,589,006.00 | 15.73 | 8.86 | 18.08 | 9.91 | 96.25 | 96.30 | 22.43 | 15.43 | 3.88 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Medpace Holdings Inc | 2.07bn | 365.57m | 10.14bn | 5.90k | 28.55 | 11.47 | 25.70 | 4.89 | 11.42 | 11.42 | 64.70 | 28.42 | 1.16 | -- | 6.85 | 350,994.30 | 20.48 | 13.94 | 43.51 | 23.18 | 29.69 | 28.84 | 17.66 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.64bn | 121.85m | 10.59bn | 1.31k | 91.16 | 8.67 | 65.98 | 6.46 | 1.22 | 1.22 | 16.30 | 12.79 | 0.489 | 0.5703 | 4.35 | 1,248,362.00 | 3.63 | -21.63 | 4.38 | -25.75 | 85.92 | 86.65 | 7.43 | -77.05 | 3.03 | -- | 0.5013 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Vaxcyte Inc | 0.00 | -507.65m | 10.71bn | 254.00 | -- | 3.13 | -- | -- | -4.55 | -4.55 | 0.00 | 27.47 | 0.00 | -- | -- | 0.00 | -20.08 | -34.22 | -20.95 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| BIO-TECHNE Corp | 1.17bn | 150.68m | 10.92bn | 3.10k | 73.09 | 5.11 | 41.67 | 9.32 | 0.9402 | 0.9402 | 7.29 | 13.46 | 0.4267 | 2.15 | 5.47 | 377,930.00 | 5.49 | 9.42 | 5.77 | 10.04 | 65.93 | 67.29 | 12.86 | 21.41 | 3.26 | 18.07 | 0.123 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Neurocrine Biosciences, Inc. | 2.24bn | 385.90m | 12.48bn | 1.70k | 33.02 | 4.59 | 30.33 | 5.57 | 3.73 | 3.73 | 21.67 | 26.87 | 0.7027 | 0.8901 | 4.99 | 1,602,000.00 | 12.09 | 9.77 | 14.67 | 12.19 | 98.52 | 98.51 | 17.21 | 14.79 | 4.26 | 10.28 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Insmed Inc | 342.96m | -864.29m | 13.00bn | 912.00 | -- | 26.89 | -- | 37.91 | -5.56 | -5.56 | 2.21 | 2.70 | 0.2031 | 0.8848 | 8.81 | 376,050.40 | -51.17 | -40.96 | -59.16 | -46.88 | 77.25 | 77.99 | -252.01 | -212.92 | 5.99 | -18.41 | 0.6702 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Data as of Nov 21 2024. Currency figures normalised to Medpace Holdings Inc's reporting currency: US Dollar USD
31.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.50m | 8.05% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.41m | 7.75% |
| Wasatch Advisors LPas of 30 Sep 2024 | 908.68k | 2.92% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 752.96k | 2.42% |
| Geode Capital Management LLCas of 30 Sep 2024 | 628.05k | 2.02% |
| Riverbridge Partners LLCas of 30 Sep 2024 | 551.64k | 1.78% |
| TD Asset Management, Inc.as of 30 Sep 2024 | 503.07k | 1.62% |
| Bessemer Investment Management LLCas of 30 Sep 2024 | 500.77k | 1.61% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 492.49k | 1.59% |
| Findlay Park Partners LLPas of 30 Sep 2024 | 470.90k | 1.52% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
